Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499655 | 1.00 | GNAI3 (0.38) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL6487784 | 0.88 | S1PR1 (0.37) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL30426265 | 0.83 | KDM4E (0.37) | — | |
| SCHEMBL6484393 | 0.79 | GBA1 (0.44) | GNAI3GNAO1GNAI1TAAR1GBA1 | |
| SCHEMBL28538299 | 0.78 | TSHR (0.38) | GNAI3GNAO1GNAI1TAAR1 | |
| SCHEMBL28180032 | 0.78 | TAAR1 (0.44) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL3106291 | 0.78 | TAAR1 (0.44) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL9261256 | 0.77 | GBA1 (0.43) | GNAI3GNAO1GNAI1TAAR1GBA1 | |
| SCHEMBL6566400 | 0.77 | TAAR1 (0.52) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL6439309 | 0.77 | TAAR1 (0.52) | GNAI3GNAO1GNAI1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911442-B1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-06-28 | — | — | US | disclosed |
| US-6803369-B1 | INHIBIT A BIOLOGICAL ACTIVITY OF A TOPOISOMERASE ENZYMES | SMITHKLINE BEECHAM CORPORATION | 2004-10-12 | — | — | US | disclosed |
| EP-1187828-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-04-21 | — | — | EP | disclosed |
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | TOP1, TOP2A, TOP2B | GNAI3 3383/4885GNAO1 2680/4885GNAI1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.